TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06366672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection
Description: live, nonreplicating vaccine delivered according to the FDA approved package insert

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Research blood draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research bronchoscopy
Description: Outpatient research bronchoscopy with bronchoalveolar lavage and endobronchial biopsy performed with conscious sedation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin punch biopsy
Description: Skin punch biopsy performed with topical anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Bone marrow aspiration performed with local anesthesia.
Study: NCT06171997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddling after bath group
Description: The babies were bathed in the bathtub. Then swaddling was done. The baby was taken into the incubator and waited for 15 minutes. At the end of 15 minutes, the swaddle was opened quietly and slowly, without disturbing the body posture. Stress and comfort scores were given by two observers by video recording the babies before bathing, before swaddling and after swaddling.~Newborns' stress will be assessed with the Newborn Stress Scale and their comfort with the Newborn Comfort Behavior Scale.
Study: NCT06267261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KOLMI® surgical face mask (OP-Air)
Description: 12 subjects are exposed to birch pollen allergen in ALYATEC EEC while wearing a KOLMI® surgical face mask (OP-Air)
Study: NCT06481826

Intervention type: DRUG
Intervention: Glofitamab
Description: Glofitamab given in standard dosage
Study: NCT05465330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and remifentanil 0.05-0.2 μg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane, Propofol
Description: After induction, anesthesia will be maintained with 0.5 MAC desflurane, propofol 1.5-2.5 μg/ml and remifentanil 0.05-0.2 μg/kg/min
Study: NCT06527976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomedine added to bupivacaine for adductor canal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone added to bupivacaine for adductor canal block
Study: NCT05077306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy group
Description: individual bedside single session of receptive music therapy (RMT) by a certified Music therapist- GIM fellow in presence. STAI Y-1 was administered 5 min. before session (STAI Y-1 PRE) and 15 min. after session (STAI Y-1 POST) in paper form. HR and O2Sat were recorded from the bedside monitor 3 times: start session (T0), 10 min. (T1), end session (T2).Participants i were asked to fill in an optional open-ended question concerning their experience with music therapy.
Study: NCT05295602

Intervention type: RADIATION
Intervention: CT scan
Description: CT of lower leg
Study: NCT04976140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PN-101
Description: PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.~3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PN-101
Description: PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.~3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose.
Study: NCT06635746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinpocetine
Description: Increasing doses of vinpocetine to assess tolerability.
Study: NCT06636136

Intervention type: DEVICE
Group type: OTHER
Intervention: OPRA
Description: Surgery
Study: NCT06636097

Intervention type: DEVICE
Intervention: Full arch
Description: design
Study: NCT06636565

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06095817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Delivered Brief Intervention (IDBI)
Description: The intervention is an online module that can be accessed through smartphone, tablet, computer or other device. Participants will receive information about alcohol expectancies, alcohol use and norms, identity (service member, veteran, civilian), sleep, stress, and strategies for coping on the job.
Study: NCT04390451

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Whole Health STEPS
Description: A peer-delivered package of Whole Health services.
Study: NCT04976140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PN-101
Description: PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.~3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose.
Study: NCT06530485

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiota-directed food
Description: MDF can modulate the gut microbiota and enhance host immunity, growth, and development in malnourished children. Each sachet of MDF (100 gm) provides approximately 500 kcal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Khichuri
Description: Khichuri is a home-based nutritious food with high energy and protein. This arm also contains zinc (10 gm/day), micronutrient powder, and an egg daily.
Study: NCT05482672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetHealthy-OA mind-body program
Description: The GetHealthy-OA mind-body program emphasizes increased physical activity, healthy diet and sleep habits to lessen osteoarthritis and depressive symptoms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The oral placebo will consist of corn starch and gelatin capsules

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health education booklet
Description: The booklet will containing brief summarized information that reflects the active intervention topics including the trajectory of pain and recovery for those with knee osteoarthritis, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living
Study: NCT06382779

Intervention type: PROCEDURE
Intervention: reverse shoulder arthroplasty
Description: resection of proximal humeral tumors and reconstruction with reverse shoulder arthroplasty

Intervention type: PROCEDURE
Intervention: reverse shoulder arthroplasty
Description: resection of proximal humeral tumors and reconstruction with reverse shoulder arthroplasty
Study: NCT05848271

Intervention type: OTHER
Intervention: Patient Registry
Description: Participants who have been diagnosed with HPDL mutations will be enrolled to patient registry.

Intervention type: OTHER
Intervention: Dry blood spots sampling
Description: Dry blood splots require 500nl of blood.
Study: NCT04601064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care Model
Description: Collaborative care (CC) is an evidence-based model of integrated mental health and substance use disorder care endorsed by the American Psychiatric Association for the integration of mental health and substance use disorder care into primary care settings. CC includes the following components: 1) A collaborative care team of multidisciplinary health care providers consisting of the primary physician, a care manager and a consulting psychiatrist, providing care in a coordinated fashion; 2) A population focus with the team working together to provide care and continuously measure and track health outcomes of a defined population of patients; 3) A measurement-guided approach with systematic use of disease specific patient reported outcome measures, such as symptom rating scales like the PHQ-9 to drive clinical decision making; and 4) Evidence-based practices with the team adapting scientifically proven treatments within an individual clinical context to achieve improved health outcomes.
Study: NCT05209490

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femoral nerve blockade under ultrasound control with a peripheral nerve stimulator
Description: Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic femoral nerve block is performed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: femoral nerve blockade under ultrasound control without a peripheral nerve stimulator
Description: Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed.
Study: NCT04916171

Intervention type: OTHER
Intervention: incidence
Description: It is aimed to determine the incidence of endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome, or to determine the incidence of polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis.

Intervention type: OTHER
Intervention: incidence
Description: It is aimed to determine the incidence of endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome, or to determine the incidence of polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis.
Study: NCT04846556

Intervention type: OTHER
Intervention: data collection
Description: data collection : gender, weight, biological data (platelets, hemoglobin, creatinine, liver function tests), performance status, type of Venous Thromboembolic Event (VTE) and cancer, anticancer and anticoagulant therapy, adverse events (bleeding, recurrence of Venous Thromboembolic Event (VTE), death) up to 6 months after their Venous Thromboembolic Event (VTE).
Study: NCT04928911

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
Study: NCT06503042

Intervention type: DRUG
Intervention: Chemotherapy combined with immunotherapy
Description: Patients in the chemotherapy combined with immunotherapy group use any chemotherapy drug in combination with any immunotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.

Intervention type: DRUG
Intervention: Chemotherapy only
Description: Patients in the chemotherapy alone group use any chemotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
Study: NCT06178679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-100 (vezocolmitide)
Description: ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Ophthalmic Solution
Study: NCT04390451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Health STEPS
Description: A peer-delivered package of Whole Health services.
Study: NCT05085600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients will begin performing the cervical stabilization exercise, and will taught to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine.~In addition, progress will continued in the exercise of the contraction of deep neck flexor muscles in other positions.~The progression of the exercises will be adapted to each patient, depending on their evolution. Firstly, exercises will undertaken in the supine and standing positions; once these positions will mastered, the exercises progressed to asymmetric positions with cervical bending and/or rotation toward each patient's most symptomatic side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy + Exercise
Description: 20-minute session. In the first 5 minutes, muscle techniques will be performed to prepare the tissue of the upper cervical spine before applying joint techniques. In the next 15 minutes, manipulation and / or mobilization techniques of the upper cervical spine, including the C2-3 segment, will be combined with cervical exercise
Study: NCT05212272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-MRI Brain Scan
Description: Before starting radiation, participants will have a PET scan and MRI scan of the brain. After 2 to 3 weeks of radiation treatments, participants will have a repeat PET scan. Then 1 month after radiation participants will have another PET scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood draws will be taken at baseline, one month after radiation treatment and 3 to 4 months after radiation treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory testing
Description: 3 sessions with simple tests to evaluate how the brain is working. These tests primarily check things like memory, attention, and thought process. The whole set of tests will take 1 hour each time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional lumbar puncture for cerebrospinal fluid collection
Description: Participants that consent for cerebrospinal fluid collection will have 6 and 20 ml of cerebrospinal collected at baseline.
Study: NCT04715555

Intervention type: DEVICE
Intervention: Electrocardiogram monitoring
Description: Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.

Intervention type: DEVICE
Intervention: Electrocardiogram monitoring
Description: Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.

Intervention type: DEVICE
Intervention: Electrocardiogram recording
Description: Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.

Intervention type: DEVICE
Intervention: Electrocardiogram recording
Description: Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.

Intervention type: DEVICE
Intervention: Photoplethysmogram monitoring
Description: Photoplethysmogram monitoring using a wearable device on the wrist.

Intervention type: DEVICE
Intervention: Photoplethysmogram monitoring
Description: Photoplethysmogram monitoring using a wearable device on the wrist.

Intervention type: OTHER
Intervention: Feedback questionnaire
Description: A questionnaire to collect feedback on participants' experiences of wearing the devices.

Intervention type: OTHER
Intervention: Feedback questionnaire
Description: A questionnaire to collect feedback on participants' experiences of wearing the devices.
Study: NCT04808245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecentriq 1200 MG in 20 ML Injection
Description: One vial of Tecentriq® (1200 mg) will be administered as an intravenous (i.v.) infusion over 60 minutes every 3 weeks starting 4 weeks after radiotherapy. If the first infusion is tolerated, all subsequent infusions will be delivered over 30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3K27M peptide vaccine
Description: The H3K27M peptide vaccine is injected subcutaneously (s.c.). For a single vaccination 300 μg of the peptide will be emulsified in a total volume of 1 ml.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imiquimod (5%)
Description: One sachet of Aldara® cream (250 mg) will be applied to an area of 5 x 5 cm around the injection site of the H3K27M peptide vaccine 15 min after vaccination and left on the skin for approximately 8 hours according to the instructions in the SmPC. 24 hours after the vaccination a second sachet of Aldara® will be applied by the patient as instructed above and left on the skin for approximately 8 hours.
Study: NCT06326268

Intervention type: DEVICE
Group type: OTHER
Intervention: Phototherapy system CareMin650TM
Description: * As part of preventive treatment: Photobiomodulation sessions will be carried out at a dose of 3 joules for 1 minute 51 seconds, 3 times a week (for a maximum duration of 4 to 6 weeks).~* As part of curative treatment (i.e. for patients developing mucositis, from grade I): photobiomodulation will be carried out at a curative dose of 6 joules daily (for a maximum duration of 4 to 6 weeks ) for 3 minutes 34 seconds.
Study: NCT05206136

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Neck and Low back muscles will be evaluated by ultrasound.

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Neck and Low back muscles will be evaluated by ultrasound.

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Neck and Low back muscles will be evaluated by ultrasound.
Study: NCT05561673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2
Description: Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
Study: NCT05535517

Intervention type: OTHER
Intervention: CeraVe SA Smoothing Cleanser
Description: The CeraVe Salicylic Acid (SA) Smoothing Cleanser is formulated with salicylic acid to help exfoliate the skin and remove dirt and dead skin cells on the skin without compromising or striping moisture from the skin's natural barrier, leaving the skin feeling clean, smooth and hydrated. This salicylic acid cleanser is also formulated to include hyaluronic acid to hydrate and retain moisture and 3 essential ceramides to moisturise and help support the skin's barrier.
Study: NCT06032208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova Dialyzer
Description: The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 5 and ending at the end of dialysis week 28. This will allow us to compare patient reported symptoms in weeks 1-4 on their usual dialyzer with with their symptoms on the Theranova dialyzer.
Study: NCT04964050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capozide
Description: Capozide will be administered as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capozide
Description: Capozide will be administered as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capozide
Description: Capozide will be administered as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-Hemmer-Ratiopharm
Description: ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-Hemmer-Ratiopharm
Description: ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-Hemmer-Ratiopharm
Description: ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence.
Study: NCT04969328

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ParTNer-STEPs
Description: The intervention is a transfer program (ParTNer-STEPs), offered to the parents 1½ - ½ year before their child´s transfer to adult care.~ParTNer-STEPs consist of~1. an informative website available for parents from recruitment until follow-up.~2. online educational events for parents. The teaching events are offered twice a year as a web based seminar with short presentations on different topics. The seminars will not be available for parents after their child has transferred to adult care.~3. transfer consultations across the paediatric and adult department. The transition consultations consist of:~   * a preparatory consultation (3-6 months before transfer) with the paediatric nurse.~  * a farewell consultation with the paediatric nurse (0-3 months before transfer).~  * a joint consultation (at transfer) where both the pediatrician and the adult physician will be present.~  * a welcoming consultation with the nurse from the adult care (0-3 months after transfer).